[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Jimbo H, Kamata S, Miura K, Asamoto S, Tada S, Endo T, Masubuchi T, Nakamura N, Fushimi C: Operative management of skull base malignant tumors arising from the nasal cavity and paranasal sinus: recent strategies used in 25 cases. Neurol Med Chir (Tokyo); 2010 Jan;50(1):20-6; discussion 26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The treatment of these tumors affecting the skull base is complex due to the significant anatomical features.
  • En bloc resections using anterior skull base resection, orbital resection, middle fossa resection, and combined procedures of these three resections were performed.
  • Using a combination of adjuvant radiation and chemotherapy, we have achieved a 2-year disease-free survival rate of 90% in these cases.
  • Here we present our recent institutional experience and treatment policy employed during the past 3 years.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / methods. Cranial Fossa, Middle / anatomy & histology. Cranial Fossa, Middle / pathology. Cranial Fossa, Middle / surgery. Drug Therapy / methods. Drug Therapy / statistics & numerical data. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Orbit / anatomy & histology. Orbit / pathology. Orbit / surgery. Osteotomy / contraindications. Osteotomy / methods. Paranasal Sinuses / anatomy & histology. Paranasal Sinuses / pathology. Paranasal Sinuses / surgery. Patient Care Team. Postoperative Complications / etiology. Postoperative Complications / physiopathology. Postoperative Complications / prevention & control. Radiotherapy, Adjuvant / methods. Radiotherapy, Adjuvant / statistics & numerical data. Reconstructive Surgical Procedures / methods. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098020.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Rieken S, Gaiser T, Mohr A, Welzel T, Witt O, Kulozik AE, Wick W, Debus J, Combs SE: Outcome and prognostic factors of desmoplastic medulloblastoma treated within a multidisciplinary treatment concept. BMC Cancer; 2010;10:450
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and prognostic factors of desmoplastic medulloblastoma treated within a multidisciplinary treatment concept.
  • Today, all medulloblastoma patients receive intensive multimodal treatment including surgery, radiotherapy and chemotherapy.
  • This study was set up to investigate treatment outcome and prognostic factors after radiation therapy in patients with desmoplastic medulloblastomas.
  • In all patients, an additional boost was delivered to the posterior fossa.
  • The median dose to the whole brain and the craniospinal axis was 35.2 Gray (Gy), and 54.4 Gy to the posterior fossa.
  • Fourteen patients received chemotherapy, including seven who were treated with combined radiochemotherapy and twelve who received adjuvant chemotherapy.
  • Treatment-associated toxicity was acceptable.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cerebellar Neoplasms / therapy. Cranial Irradiation. Medulloblastoma / therapy. Neoplasm Recurrence, Local / therapy. Neurosurgical Procedures
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2127-36 [10561268.001]
  • [Cites] Pediatr Blood Cancer. 2010 Apr;54(4):635-7 [20146217.001]
  • [Cites] Neurosurgery. 2000 Sep;47(3):623-31; discussion 631-2 [10981749.001]
  • [Cites] Neuro Oncol. 2001 Jan;3(1):29-34 [11305414.001]
  • [Cites] J Neurooncol. 2002 Aug;59(1):49-61 [12222838.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):855-60 [12377339.001]
  • [Cites] Neurol India. 2003 Mar;51(1):27-34 [12865511.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):755-61 [14529781.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1161-4 [15001259.001]
  • [Cites] Radiology. 1969 Dec;93(6):1351-9 [4983156.001]
  • [Cites] Cancer. 1971 Oct;28(4):977-83 [5111749.001]
  • [Cites] J Neurosurg. 1990 Apr;72(4):572-82 [2319316.001]
  • [Cites] Eur J Cancer. 1990 Apr;26(4):464-9 [2141512.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Aug;19(2):265-74 [2394606.001]
  • [Cites] Am J Clin Oncol. 1992 Jun;15(3):207-11 [1590272.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):616-22 [8478656.001]
  • [Cites] Cancer. 1994 Oct 15;74(8):2352-60 [7922986.001]
  • [Cites] Acta Neurochir (Wien). 1994;127(1-2):65-8 [7942185.001]
  • [Cites] Am J Pathol. 1995 Feb;146(2):472-80 [7856756.001]
  • [Cites] Acta Neurochir (Wien). 1995;132(1-3):59-65 [7754860.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):1145-52 [7607936.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):1255-7 [7607951.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):951-7 [7607969.001]
  • [Cites] Pediatr Neurosurg. 1996;24(4):167-176; discussion 176-7 [8873158.001]
  • [Cites] J Neurooncol. 1997 Nov;35(2):169-76 [9266455.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):832-45 [10071274.001]
  • [Cites] Cancer. 1999 Jul 1;86(1):142-8 [10391574.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):978-86 [15758008.001]
  • [Cites] J Neurol. 2005 Mar;252(3):291-9 [16189725.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Jun;28(6):374-8 [16794506.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4202-8 [16943538.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):433-40 [17498567.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Med Oncol. 2008;25(1):69-72 [18188718.001]
  • [Cites] Strahlenther Onkol. 2008 Jan;184(1):8-14 [18188517.001]
  • [Cites] J Clin Oncol. 2009 Apr 1;27(10):1627-36 [19255330.001]
  • [Cites] Cancer. 2000 Jun 15;88(12):2887 [10870076.001]
  • (PMID = 20731859.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2939548
  •  go-up   go-down


3. Hayashi T, Kuroshima Y, Yoshida K, Kawase T, Ikeda E, Mukai M: Primary osteosarcoma of the sphenoid bone with extensive periosteal extension--case report. Neurol Med Chir (Tokyo); 2000 Aug;40(8):419-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography (CT) and magnetic resonance imaging revealed an anterior middle cranial fossa tumor extending into both the orbit and the extracranial space.
  • The histological diagnosis was osteosarcoma.
  • The patient was treated with chemotherapy and radiation therapy, but died of tumor recurrence 10 months after the surgery.
  • [MeSH-major] Bone Neoplasms / diagnosis. Osteosarcoma / diagnosis. Periosteum / pathology. Periosteum / radiography
  • [MeSH-minor] Adult. Combined Modality Therapy. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness / diagnosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10979265.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


Advertisement
4. Hu X, Bao Y, Zhang L, Cheng Y, Li K, Wang W, Liu Y, He H, Sun Z, Zhuang T, Wang Y, Chen J, Liang Y, Zhang Y, Zhao H, Wang F, Chen M: [A prospective randomized study of the radiotherapy volume for limited-stage small cell lung cancer: a preliminary report]. Zhongguo Fei Ai Za Zhi; 2010 Jul;13(7):691-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVE: Controversies exists with regard to target volumes as far as thoracic radiotherapy (TRT) is concerned in the multimodality treatment for limited-stage small cell lung cancer (LSCLC).
  • The aim of this study is to prospectively compare the local control rate, toxicity profiles, and overall survival (OS) between patients received different target volumes irradiation after induction chemotherapy.
  • METHODS: LSCLC patients received 2 cycles of etoposide and cisplatin (EP) induction chemotherapy and were randomly assigned to receive TRT to either the post- or pre-chemotherapy tumor extent (GTV-T) as study arm and control arm, CTV-N included the positive nodal drainage area for both arms.
  • One to 2 weeks after induction chemotherapy, 45 Gy/30 Fx/19 d TRT was administered concurrently with the third cycle of EP regimen.
  • Prophylactic cranial irradiation (PCI) was administered to patients with a complete response.
  • The local recurrence rates were 32.4% and 28.2% respectively (P = 0.80); the isolated nodal failure (INF) rates were 3.0% and 2.6% respectively (P = 0.91); all INF sites were in the ipsilateral supraclavicular fossa.
  • Grade 0-I and II-III late pulmonary injury was developed in 97.1%, 2.9% and 86.4%, 15.4% patients respectively (P = 0.07).
  • Median survival time was 22.1 months and 26.9 months respectively.
  • CONCLUSIONS: The preliminary results of this study indicate that irradiant the post-chemotherapy tumor extent (GTV-T) and positive nodal drainage area did not decrease local control and overall survival while radiation toxicity was reduced.
  • [MeSH-major] Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Small Cell Lung Carcinoma / drug therapy. Small Cell Lung Carcinoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Drug Administration Schedule. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Follow-Up Studies. Humans. Lung Injury / etiology. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Radiotherapy / adverse effects. Radiotherapy / methods. Radiotherapy Dosage. Survival Analysis. Thrombocytopenia / etiology. Time Factors. Treatment Outcome. Tumor Burden / drug effects. Tumor Burden / radiation effects

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20673485.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Li Y, Zhang TM, An YZ, Shi JT, Fu JD, Qiu E: [Clinical study of lacrimal gland tumor involving anterior and middle cranial fossae]. Zhonghua Yi Xue Za Zhi; 2006 Jun 20;86(23):1597-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study of lacrimal gland tumor involving anterior and middle cranial fossae].
  • OBJECTIVE: To investigate the clinical manifestations of lacrimal gland tumor involving the anterior and middle cranial fossae and the effect of transcranial-orbital approach in treatment of such tumor.
  • METHODS: A retrospective study was conducted on the clinical data of 23 cases lacrimal gland tumor involving the anterior and middle cranial fossae confirmed by radiological examination, including 11 cases of adenoid cystic carcinoma, 6 cases of pleomorphic adenocarcinoma (malignant mixed tumor), 2 cases of adenocarcinoma, 1 case of squamous cell carcinoma, 1 case of ductal carcinoma, 1 case of mucoepidermoid carcinoma, and 1 case of benign mixed tumor, 15 males and 8 females, aged 42.5 (2 - 76), with a case history of 43 months (2 months to 27 years), with the chief complaints of progressive proptosis, disgenesia of the eye ball, and orbit pain, all undergoing transcranial-orbital operation from August 1998 to February. 2006.
  • CONCLUSIONS: Malignant lacrimal gland tumors, mainly adenoid cystic carcinomas, incline to involve the anterior and middle cranial fossae.
  • Suitable treatment strategy should by combination of operation with irradiation or chemotherapy.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Cranial Fossa, Anterior. Cranial Fossa, Middle. Craniotomy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16854296.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


6. Nakaguchi H, Matsuno A, Miyawaki S, Murakami M, Yamada M, Yamazaki K, Ishida Y: Small cell carcinoma originating from the cavernous sinus. Acta Neurochir (Wien); 2010 Mar;152(3):493-500

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Post-contrast T1-weighted MRI revealed a mass lesion of 3-cm maximum size occupying the right cavernous sinus and extending to the right middle cranial fossa.
  • After biopsy via the frontozygomatic approach, one radiosurgery treatment was followed by four cycles of chemotherapy (cisplatin together with VP-16 therapy), after which the lesion diminished dramatically in size.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy. Cavernous Sinus Thrombosis / etiology. Cavernous Sinus Thrombosis / pathology. Cerebral Veins / physiopathology. Cerebrovascular Circulation / physiology. Cranial Fossa, Middle / pathology. Craniotomy. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness / pathology. Ophthalmoplegia / etiology. Ophthalmoplegia / physiopathology. Radiotherapy. Sella Turcica / anatomy & histology. Sella Turcica / pathology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19434364.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. De Ruysscher D, Bremer RH, Koppe F, Wanders S, van Haren E, Hochstenbag M, Geeraedts W, Pitz C, Simons J, ten Velde G, Dohmen J, Snoep G, Boersma L, Verschueren T, van Baardwijk A, Dehing C, Pijls M, Minken A, Lambin P: Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: a phase II trial. Radiother Oncol; 2006 Sep;80(3):307-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chest radiotherapy to a dose of 45 Gy in 30 fractions in 3 weeks (1.5 Gy BID with 6 - 8 h interval) was delivered concurrently with carboplatin and etoposide chemotherapy.
  • Chest radiation started after a mean time of 17.7 days +/- 9.7 days (SD) (range: 0-33 days) after the beginning of chemotherapy.
  • Only the primary tumour and the positive nodal areas on the pre-treatment CT scan were irradiated.
  • A total of five chemotherapy cycles were administered, followed by prophylactic cranial irradiation (PCI) in patients without disease progression.
  • RESULTS: After a median time of 18 months post-radiotherapy, 7 patients (26%, 95% CI 19.5-42.5%) developed a local recurrence.
  • Three patients (crude rate 11%, 95% CI 2.4-29%), developed an isolated nodal failure, all of them in the ipsilateral supraclavicular fossa.
  • Eight patients developed an acute, reversible grade 3 (CTC 3.0) radiation oesophagitis (30%, 95% CI 14-50%).
  • CONCLUSIONS: Because of the small sample size, no definitive conclusions can be drawn.
  • However, the omission of elective nodal irradiation on the basis of CT scans in patients with LD-SCLC resulted in a higher than expected rate of isolated nodal failures in the ipsilateral supraclavicular fossa.
  • In the mean time, elective nodal irradiation should only be omitted in clinical trials.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiotherapy. Carcinoma, Small Cell / radiotherapy. Lung Neoplasms / radiotherapy. Lymph Nodes / radiation effects. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiation Pneumonitis / etiology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16949169.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


8. Apostolopoulos K, Ferekidis E: Extensive primary Ewings' sarcoma in the greater wing of the sphenoid bone. ORL J Otorhinolaryngol Relat Spec; 2003 Jul-Aug;65(4):235-7
Genetic Alliance. consumer health - Ewing's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a rare case of an extensive primary cranial Ewing's sarcoma located in the greater wing of the sphenoid bone with extension to the orbit, the endocranium, the parapharyngeal and infratemporal space.
  • The prognosis of Ewing's sarcoma in the absence of surgery is uncertain, but prompt treatment appears to have a satisfactory therapeutic outcome.
  • In the future, more cases should be studied in order to investigate the biological behaviour of a primary cranial Ewing's sarcoma.
  • [MeSH-major] Sarcoma, Ewing / diagnosis. Sarcoma, Ewing / drug therapy. Skull Neoplasms / diagnosis. Skull Neoplasms / drug therapy. Sphenoid Bone / pathology
  • [MeSH-minor] Adult. Cranial Fossa, Middle / pathology. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Orbit / pathology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 14564101.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


9. Gorelick J, Ross D, Marentette L, Blaivas M: Sinonasal undifferentiated carcinoma: case series and review of the literature. Neurosurgery; 2000 Sep;47(3):750-4; discussion 754-5
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SNUC tends to present with advanced-stage disease, often with intracranial invasion, and requires an aggressive treatment approach that includes surgical resection.
  • INTERVENTION: All four patients underwent multimodal treatment with chemotherapy, radiotherapy (60-65 Gy), and aggressive surgical resection via a combined bifrontal craniotomy and a subcranial approach to the anterior cranial fossa.
  • Three of four patients died as a result of their disease, an average of 15 months after diagnosis.
  • Only one patient remains alive, although with metastatic intracranial disease, at 24 months after diagnosis.
  • CONCLUSION: SNUC is a rare neoplasm with a poor prognosis despite an aggressive multimodal approach to treatment.
  • On the basis of our experience, we advocate radical resection as part of the initial combined therapy for patients who present with locally advanced, nonmetastatic disease but we suggest reserving surgery for patients with early brain invasion until there has been a radiographically proven central nervous system response to adjuvant therapy.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Craniotomy. Female. Frontal Lobe / pathology. Frontal Lobe / surgery. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Sinonasal undifferentiated carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10981763.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 16
  •  go-up   go-down


10. Ganly I, Gross ND, Patel SG, Bilsky MH, Shah JP, Kraus DH: Outcome of craniofacial resection in patients 70 years of age and older. Head Neck; 2007 Feb;29(2):89-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seventeen (47%) patients had had prior single-modality or combined treatment, which included surgery in 14 (40%), radiation in 13 (36%), and chemotherapy in 2 (6%).
  • Adjuvant radiotherapy was given in 15 (42%) and chemotherapy in 1 (3%).
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Carcinoma / mortality. Carcinoma / pathology. Carcinoma / surgery. Cranial Fossa, Anterior / surgery. Cranial Fossa, Middle / surgery. Databases as Topic. Esthesioneuroblastoma, Olfactory / mortality. Esthesioneuroblastoma, Olfactory / pathology. Esthesioneuroblastoma, Olfactory / surgery. Female. Follow-Up Studies. Humans. Male. Melanoma / mortality. Melanoma / pathology. Melanoma / surgery. Neoplasm Recurrence, Local. Prospective Studies. Surgical Flaps. Survival Analysis


11. Raney RB, Meza J, Anderson JR, Fryer CJ, Donaldson SS, Breneman JC, Fitzgerald TJ, Gehan EA, Michalski JM, Ortega JA, Qualman SJ, Sandler E, Wharam MD, Wiener ES, Maurer HM, Crist WM: Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997. Med Pediatr Oncol; 2002 Jan;38(1):22-32
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997.
  • BACKGROUND: We reviewed 611 patients with parameningeal sarcoma entered on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols-II through IV (1978-1997), to delineate treatment results and evaluate prognostic factors.
  • PROCEDURE: Primary sites were the middle ear/mastoid (N = 138), nasopharynx/nasal cavity (N = 235), paranasal sinuses (N = 132), parapharyngeal region (N = 29), and the pterygopalatine/infratemporal fossa (N = 77).
  • Treatment was initial biopsy or surgery followed by multiagent chemotherapy and radiation therapy (XRT).
  • Beginning in 1977, patients with cranial nerve palsy, cranial base bony erosion, and/or intracranial extension at diagnosis were considered as having meningeal involvement.
  • They received triple intrathecal medications, whole brain XRT, and then spinal XRT.
  • These treatments were successively eliminated from 1980 to 1991.
  • Favorable prognostic factors were: age 1-9 years at diagnosis; primary tumor in the nasopharynx/nasal cavity, middle ear/mastoid, or parapharyngeal areas; no meningeal involvement; and non-invasive tumors (T1).
  • Thirty-five of 526 patients (6.7%) with information about presence/absence of meningeal involvement at diagnosis developed central nervous system (CNS) extension at 5-164 weeks (median, 46 weeks) after starting therapy.
  • CONCLUSIONS: Biopsy, XRT to the target volume, and systemic chemotherapy are successful treatments for the large majority of patients with localized parameningeal sarcoma.
  • [MeSH-major] Head and Neck Neoplasms / therapy. Meningeal Neoplasms / therapy. Outcome Assessment (Health Care). Rhabdomyosarcoma / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Clinical Protocols. Combined Modality Therapy. Cytarabine / administration & dosage. Female. Humans. Hydrocortisone / administration & dosage. Infant. Infant, Newborn. Injections, Spinal. Male. Methotrexate / administration & dosage. Neoplasm Invasiveness. Prognosis. Radiation Dosage. Randomized Controlled Trials as Topic. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley‐Liss, Inc.
  • (PMID = 11835233.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-24507; United States / NCI NIH HHS / CA / CA-29511; United States / NCI NIH HHS / CA / CA-72989
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


12. Ang C, Hauerstock D, Guiot MC, Kasymjanova G, Roberge D, Kavan P, Muanza T: Characteristics and outcomes of medulloblastoma in adults. Pediatr Blood Cancer; 2008 Nov;51(5):603-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment regimens have typically been modeled after pediatric protocols.
  • METHODS: Medical records were reviewed to gather demographic and clinical data including presenting symptoms, tumor characteristics, management, survival, and treatment toxicity.
  • The median age at diagnosis was 30 (range 17-48).
  • Median OS was 108 months and median progression-free survival time was 63 months.
  • Age, sex, risk, stage, extent of resection, chemotherapy and time between surgery and adjuvant therapy did not significantly influence survival outcomes.
  • Late relapses, especially in the posterior fossa, are a significant problem.
  • Further follow-up will be required to ascertain the effect of adjuvant chemotherapy on survival.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebellar Neoplasms / therapy. Medulloblastoma / pathology. Medulloblastoma / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Chemotherapy, Adjuvant / adverse effects. Combined Modality Therapy. Cranial Irradiation. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Neurosurgical Procedures. Radiotherapy, Adjuvant / adverse effects. Salvage Therapy / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18649371.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Germanwala AV, Mai JC, Tomycz ND, Niranjan A, Flickinger JC, Kondziolka D, Lunsford LD: Boost Gamma Knife surgery during multimodality management of adult medulloblastoma. J Neurosurg; 2008 Feb;108(2):204-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nine patients also received systemic chemotherapy.
  • Stereotactic radiosurgery was applied to residual and recurrent posterior fossa tumor as well as to foci of intracranial medulloblastoma metastases.
  • The median time interval from initial diagnosis and resection to the first GKS treatment was 24 months (range 2-37 months).
  • CONCLUSIONS: Single or multiple GKS sessions were a well-tolerated, feasible, and effective adjunctive treatment for posterior fossa residual or recurrent medulloblastoma as well as intracranial metastatic medulloblastoma in adult patients.
  • [MeSH-major] Cerebellar Neoplasms / surgery. Medulloblastoma / surgery. Neoadjuvant Therapy. Radiosurgery / methods
  • [MeSH-minor] Adult. Age Factors. Chemotherapy, Adjuvant. Cranial Irradiation. Disease Progression. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual. Neuroectodermal Tumors / radiotherapy. Neuroectodermal Tumors / surgery. Remission Induction. Retrospective Studies. Spine / radiation effects. Supratentorial Neoplasms / radiotherapy. Supratentorial Neoplasms / surgery. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18240913.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Pallini R, Sabatino G, Doglietto F, Lauretti L, Fernandez E, Maira G: Clivus metastases: report of seven patients and literature review. Acta Neurochir (Wien); 2009 Apr;151(4):291-6; discussion 296

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In spite of radiotherapy and chemotherapy, the mean survival was 12 months.
  • CONCLUSION: Though exceedingly rare, metastases involving the clivus should be considered in the differential diagnosis with clivus chordoma.
  • The trans-sphenoidal approach is the ideal procedure to establish a histopathological diagnosis.
  • [MeSH-major] Carcinoma / secondary. Cranial Fossa, Posterior / pathology. Skull Base Neoplasms / secondary
  • [MeSH-minor] Abducens Nerve Diseases / etiology. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Liver Neoplasms / pathology. Lung Neoplasms / pathology. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Prostatic Neoplasms / pathology. Skin Neoplasms / pathology. Survival Rate. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19259614.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 30
  •  go-up   go-down


15. Ganly I, Patel SG, Singh B, Kraus DH, Bridger PG, Cantu G, Cheesman A, De Sa G, Donald P, Fliss DM, Gullane P, Janecka I, Kamata SE, Kowalski LP, Levine PA, Medina dos Santos LR, Pradhan S, Schramm V, Snyderman C, Wei WI, Shah JP: Craniofacial resection for malignant melanoma of the skull base: report of an international collaborative study. Arch Otolaryngol Head Neck Surg; 2006 Jan;132(1):73-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To report postoperative mortality, complications, and outcomes in a subset of patients with the histologic diagnosis of malignant melanoma extracted from an existing database of a large cohort of patients accumulated from multiple institutions.
  • Of the 53 patients, 25 (47%) had had prior single modality or combined treatment, which included surgery in 22 (42%), radiation in 11 (21%), and chemotherapy in 2 (4%).
  • Adjuvant radiotherapy was given in 22 (42%), chemotherapy in 3 (6%), and vaccine or interferon therapy in 2 (4%).
  • The extent of orbital involvement and adjuvant postoperative radiation therapy (PORT) were independent predictors of DSS and OS on multivariate analysis, whereas only PORT was an independent predictor of RFS.
  • [MeSH-major] Cranial Fossa, Anterior / surgery. Facial Bones / surgery. Melanoma / surgery. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Humans. International Cooperation. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16415433.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Tsai VW, Rybak L, Espinosa J, Kuhn MJ, Kamel OW, Mathews F, Glatz FR: Primary B-cell lymphoma of the clivus: case report. Surg Neurol; 2002 Sep-Oct;58(3-4):246-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, it is uncommon for a primary non-Hodgkin's lymphoma to present with cranial nerve palsies; reports in the literature are rare.
  • An endoscopic transsphenoidal procedure was performed for diagnosis and partial resection of the mass.
  • [MeSH-major] Cranial Fossa, Posterior / surgery. Lymphoma, B-Cell / surgery. Lymphoma, Large B-Cell, Diffuse / surgery. Skull Base Neoplasms / surgery
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy. Chemotherapy, Adjuvant. Combined Modality Therapy. Endoscopy. Female. Humans. Infant, Newborn. Magnetic Resonance Imaging. Middle Aged. Neoplasm, Residual / diagnosis. Neoplasm, Residual / drug therapy. Neoplasm, Residual / pathology. Neoplasm, Residual / surgery. Tomography, Emission-Computed. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12480233.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


17. Rao G, Klimo P Jr, Jensen RL, MacDonald JD, Couldwell WT: Surgical strategies for recurrent craniofacial meningiomas. Neurosurgery; 2006 May;58(5):874-80; discussion 874-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Recurrent cranial base meningiomas are among the most difficult tumors to treat surgically.
  • Although they are histologically benign, these tumors often invade through the cranial base into the infratemporal and pterygopalatine fossae.
  • We reviewed our experience with these tumors to describe the natural history of these lesions as well as provide a possible treatment paradigm.
  • METHODS: Between 2000 and 2004, seven patients with meningiomas recurring through the cranial base into facial structures were treated at the University of Utah.
  • The original site of tumor was the sphenoid wing in four patients, the middle fossa in two patients, and the left frontal region in one patient.
  • All but one patient had adjunctive therapy (including either radiation or chemotherapy) before recurrence into the face.
  • CONCLUSION: Meningiomas that recur into facial structures present a unique treatment challenge.
  • These lesions have a high rate of recurrence once they have invaded through the cranial base.
  • [MeSH-major] Facial Neoplasms / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasm Recurrence, Local / surgery. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neurosurgical Procedures / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16639321.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Schönegger K, Gelpi E, Prayer D, Dieckmann K, Matula C, Hassler M, Hainfellner JA, Marosi C: Recurrent and metastatic clivus chordoma: systemic palliative therapy retards disease progression. Anticancer Drugs; 2005 Nov;16(10):1139-43
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent and metastatic clivus chordoma: systemic palliative therapy retards disease progression.
  • Within the first 4 years, the patient underwent surgery four times.
  • Thereafter, he received radiotherapy and subsequent chemotherapy.
  • Stabilization of disease was achieved repeatedly for variable periods under local radiotherapy, systemic chemotherapy, immunomodulatory and anti-angiogenic therapy with isotretinoin and interferon-alpha, followed by thalidomide.
  • Due to the occurrence of brain and lung metastases 8 years after initial diagnosis, liposomal doxorubicin was added to thalidomide.
  • Our observations show that multimodal therapy including a systemic palliative approach is associated with long quiescent intervals in recurrent chordoma and with regression of its metastases.
  • Use of substances with high efficacy on tumor tissue and low toxicity, allowing long-term administration, seems promising in similar situations.
  • [MeSH-major] Chordoma / secondary. Chordoma / therapy. Cranial Fossa, Posterior. Neoplasm Recurrence, Local / therapy. Palliative Care. Skull Base Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Disease Progression. Humans. Karnofsky Performance Status. Male. Middle Aged. Recurrence. Treatment Outcome

  • Genetic Alliance. consumer health - Chordoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16222158.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


19. Spatola C, Privitera G: Recurrent intracranial hemangiopericytoma with extracranial and unusual multiple metastases: case report and review of the literature. Tumori; 2004 Mar-Apr;90(2):265-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The neoplasm was located in the posterior fossa.
  • The patient underwent primary surgery in 1990, not followed by any adjuvant therapy because of the histopathological diagnosis of meningioma.
  • After being free from disease for eight years she developed a local recurrence in 1998.
  • Subtotal excision of the tumor, which was finally identified as a hemangiopericytoma, was carried out, followed by adjuvant radiotherapy (64 Gy).
  • A radical metastasectomy was performed, followed by systemic chemotherapy.
  • One year later (2001) the tumor recurred again intracranially and a metastases was detected in the right breast, so the patient again underwent cranial irradiation (40 Gy) and second-line chemotherapy.
  • She died in September 2002, 12 years after the diagnosis.
  • We may conclude that, despite the tumor's natural tendency to recur several times and the ability of intracranial hemangiopericytoma to spread outside the CNS, it is possible to ensure a long survival time.
  • [MeSH-major] Brain Neoplasms / pathology. Hemangiopericytoma / secondary. Hemangiopericytoma / therapy. Neoplasm Recurrence, Local
  • [MeSH-minor] Breast Neoplasms / secondary. Breast Neoplasms / therapy. Fatal Outcome. Female. Humans. Kidney Neoplasms / secondary. Kidney Neoplasms / therapy. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Magnetic Resonance Imaging. Middle Aged

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15237597.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


20. Devaiah AK, Larsen C, Tawfik O, O'Boynick P, Hoover LA: Esthesioneuroblastoma: endoscopic nasal and anterior craniotomy resection. Laryngoscope; 2003 Dec;113(12):2086-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors advocate this method with excision with anterior craniotomy for removal of cribriform plate or anterior cranial fossa tumor extension.
  • METHODS: Patients were excluded for nonsurgical treatment or nasal and sinus tumor excision by nonendoscopic techniques.
  • Patient demographics, tumor histological findings, presenting signs and symptoms, staging (Kadish and Dulguerov), postoperative complications, adjunct therapy, and recurrence were examined.
  • All patients received radiation therapy, and one also received chemotherapy.
  • CONCLUSION: Endoscopic excision of the nasal and sinus component with anterior craniotomy for cribriform or anterior cranial fossa extension is an effective treatment of esthesioneuroblastoma.
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Postoperative Complications. Retrospective Studies


21. Rawlins JM, Batchelor AG, Liddington MI, Towns G: Tumor excision and reconstruction of the upper cervical spine: a multidisciplinary approach. Plast Reconstr Surg; 2004 Nov;114(6):1534-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Axis, Cervical Vertebra / surgery. Cervical Atlas / surgery. Chondrosarcoma / surgery. Chordoma / surgery. Cranial Fossa, Posterior / surgery. Osteosarcoma / surgery. Patient Care Team. Skull Base Neoplasms / surgery. Spinal Neoplasms / surgery
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Transplantation. Chemotherapy, Adjuvant. Combined Modality Therapy. Etoposide / administration & dosage. Fatal Outcome. Female. Femoral Neoplasms / drug therapy. Femoral Neoplasms / pathology. Femoral Neoplasms / radiotherapy. Femoral Neoplasms / surgery. Humans. Ifosfamide / administration & dosage. Interdisciplinary Communication. Internal Fixators. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Male. Methotrexate / administration & dosage. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Palliative Care. Protons / therapeutic use. Remission Induction. Spinal Fusion. Surgical Flaps

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15509945.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons; 6PLQ3CP4P3 / Etoposide; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down






Advertisement